BNTC (Benitec Biopharma) Cyclically Adjusted PS Ratio: (As of Jul. 08, 2026)


BNTC Benitec Biopharma Inc BNTC
34 GF Score
Price $13.44
View Full Analysis

What is Benitec Biopharma Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Benitec Biopharma  (NAS:BNTC) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Benitec Biopharma Cyclically Adjusted PS Ratio Related Terms


Benitec Biopharma Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Benitec Biopharma's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Benitec Biopharma Cyclically Adjusted PS Ratio Chart

Benitec Biopharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Benitec Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BNTC vs IPSC, FBRX, AUTL: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Benitec Biopharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Benitec Biopharma Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benitec Biopharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Benitec Biopharma's Cyclically Adjusted PS Ratio falls into.


BNTC
34GF Score
Benitec Biopharma Inc BNTC
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Benitec Biopharma Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Benitec Biopharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Benitec Biopharma's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/330.2130*330.2130
=0.000

Current CPI (Mar. 2026) = 330.2130.

Benitec Biopharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.107 241.018 0.147
201609 0.174 241.428 0.238
201612 0.172 241.432 0.235
201703 0.269 243.801 0.364
201706 -0.167 244.955 -0.225
201709 0.145 246.819 0.194
201712 0.335 246.524 0.449
201803 0.143 249.554 0.189
201806 -3.341 251.989 -4.378
201809 0.000 252.439 0.000
201812 0.000 251.233 0.000
201903 0.000 254.202 0.000
201906 0.000 256.143 0.000
201909 0.647 256.759 0.832
201912 1.262 256.974 1.622
202003 0.444 258.115 0.568
202006 -0.615 257.797 -0.788
202009 0.846 260.280 1.073
202012 0.004 260.474 0.005
202103 0.004 264.877 0.005
202106 0.004 271.696 0.005
202109 0.000 274.310 0.000
202112 0.052 278.802 0.062
202203 0.100 287.504 0.115
202206 0.000 296.311 0.000
202209 0.000 296.808 0.000
202212 0.009 296.797 0.010
202303 0.033 301.836 0.036
202306 0.004 305.109 0.004
202309 0.000 307.789 0.000
202312 0.000 306.746 0.000
202403 0.000 312.332 0.000
202406 0.000 314.175 0.000
202409 0.000 315.301 0.000
202412 0.000 315.605 0.000
202503 0.000 319.799 0.000
202506 0.000 322.561 0.000
202509 0.000 324.800 0.000
202512 0.000 324.054 0.000
202603 0.000 330.213 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Benitec Biopharma Business Description

Address 3940 Trust Way, Hayward, CA, USA, 94545
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
34GF Score

Get the complete analysis for BNTC

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.44
Price